North Dakota Police Can Now Legally Use Taser Drones
It’s a classic case of unintended consequences. A Republican lawmaker in North Dakota put forth legislation meant to prevent law enforcement officials from using unmanned aerial vehicles to conduct surveillance on private property without a warrant. It was transformed by fellow lawmakers into a bill allowing the police to mount Tasers, pepper spray, sound cannons and other “less-than-lethal” weapons on flying drones.
The legislation, House Bill 1328, was passed and signed into law earlier this year, but got little attention until this week, when a Daily Beast report pointed out the implications of the legislation: Law enforcement officers many miles away from suspects could have the authority to stun or otherwise incapacitate them.
Related: Ben Carson’s Idea for Controlling the Border – Military Drone Attacks
To be clear, the fact that something like this is technically legal doesn’t mean that state and local police departments will necessarily embrace the practice of remotely subduing suspects. Police officers are generally subject to local and departmental rules that can substantially limit what tactics are allowed.
The original version of the bill included language that would have barred law enforcement from mounting weapons of any kind on a drone: “A state agency may not authorize the use of, including granting a permit to use, an unmanned aircraft armed with any lethal or nonlethal weapons, including firearms, pepper spray, bean bag guns, mace, and sound-based weapons,” it said.
Supporters of the state’s police union introduced an amendment to the bill that would allow less-than-lethal weapons to be mounted on drones, according to the Daily Beast’s Justin Glawe. The amended bill was ultimately passed and signed into law.
Related: Europe Faces Up to Flight Safety Threat Posed by Drones
State Rep. Rick Becker this spring voiced his dismay at the changes to the bill in a public hearing, saying, “In my opinion there should be a nice, red line: Drones should not be weaponized. Period.”
Drones have, of course, been weaponized for years — the strikes just haven’t been in the U.S. If North Dakota is taking the lead, however, that might be about to change.
Top Reads from The Fiscal Times
- Trump Turns a Covetous Eye Toward Evangelical Voters
- Are Immigrants Really Taking American Jobs?
- Why the New Debt Ceiling Deadline Could Be Crucial
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.